Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer
AsherBio
Phase 0 Intratumoral Microdevice Study of FX-909 in Bladder Cancer Demonstrates On-Target Anti-Tumor Activity and Immune Modulation, Enhanced in Combination with Anti-PD-1
AsherBio
AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC)
AsherBio
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
AsherBio
Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC) 2026 ASCO Genitourinary Cancers Symposium
AsherBio
Phase 1 Clinical Data Show FX-909, a First-in-Class Oral PPARG Inhibitor, Drives Immune Modulation and Pro-Inflammatory Cytokine Induction in IO-Experienced Patients with Advanced Urothelial Carcinoma
AsherBio
Safety and Clinical Activity of FX-909, a First-in-Class Oral Small Molecule Inhibitor of Peroxisome Proliferator-Activated Receptor Gamma (PPARG), the Master Regulator of Luminal Lineage, in Patients with Advanced Urothelial Carcinoma
AsherBio
Webinar Presentation of FX-909 Phase 1 Part A Data in Advanced Solid Malignancies Including Advanced Urothelial Carcinoma
AsherBio
FX-909 Phase 1 Part A Data in Advanced Solid Malignancies Including Advanced Urothelial Carcinoma
AsherBio
PPARG Protein Expression in Advanced Urothelial Carcinoma May Provide a Precision Approach to Potentially Select for Response to FX-909, a First-in-Class PPARG-Targeting Agent